Reviewer's report

Title: Follow-up of Phase I Trial of Adalimumab and Rosiglitazone in FSGS: III. Report of the FONT Study Group

Version: 1 Date: 20 November 2009

Reviewer: Therese Jungraithmayr

Reviewer's report:

The present follow up report is an important attempt to find new medications to slow disease progress in steroid resistant FSGS. Though only a few patients were followed for a short observation period with results difficult to discuss, this paper might be a basis for development of innovative treatment options in this disease.

Discretionary revisions:

1. The introduction should include a short reminder, in which field of medicine the 2 medications have been used before, with which effect / success and the most important side effects.

2. Five patients start with a GFRe between 250 and 300 ml/min/1.73m². This is unphysiological, maybe you could provide the raw data (creatinine) and an explanation

3. 24% reach ESRD versus 30% who stabilize their eGFR with either medication during the observation period. What would be the percentages only with ACE inhibitors or ATB treatment? You might discuss

4. If patients passed their 18th birthday during study period which formula to calculate eGFR was used?

5. Have you considered a biopsy as possible endpoint to determine the status of fibrosis / sclerosis ?